An Exploratory Study of the Salivary Immunoglobulin A Responses to 1 Dose of a Norovirus Virus-Like Particle Candidate Vaccine in Healthy Adults. (10th September 2018)

• Record Type: Journal Article
• Authors: Atmar, Robert L; Cramer, Jakob P; Baehner, Frank; Han, Cong; Borkowski, Astrid; Mendelman, Paul M
• Is Part Of: Journal of infectious diseases. Volume 219:Number 3(2019)
• Page Start: 410
• Page End: 414
• Publication Date: 2018-09-10
• Subjects: norovirus -- vaccine -- IgA -- salivary -- immunogenicity; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiy529
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: As noroviruses are transmitted through the fecal–oral route, we investigated humoral and mucosal (salivary immunoglobulin A [IgA]) immune responses in a phase 2 trial of Takeda's bivalent norovirus virus-like particle (VLP) vaccine candidate in 50 healthy 18- to 49-year-olds. The vaccine had an acceptable tolerability profile and induced rapid, robust humoral immune responses after 1 intramuscular dose of vaccine candidate. Seroresponses were evident 8 days after vaccination as panimmunoglobulin, IgA, and histo-blood group antigen–blocking antibodies against both vaccine GI.1 and GII.4c genotypes. Salivary IgA levels were approximately 1000-fold lower than serum concentrations, and moderately or strongly correlated with the serum IgA titers at all time-points. Abstract : A bivalent norovirus virus-like particle vaccine administered intramuscularly induced salivary immunoglobulin A (IgA) responses to the homologous vaccine antigen that correlated with observed serum IgA responses.